Literature DB >> 31245112

Who will suffer from hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.

Motoko Tachihara1, Yoshihiro Nishimura1.   

Abstract

Entities:  

Year:  2019        PMID： 31245112      PMCID： PMC6560586          DOI： 10.21037/jtd.2019.04.76

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  3 in total

1.  Prognostic value of PD-1, PD-L1 and P53 in patients with non-small cell lung cancer after postoperative adjuvant chemoradiotherapy.

Authors:  Aizhong Qu; Jiliang Han; Jianfeng Zhu
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

2.  Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer.

Authors:  M P Petrova; I S Donev; M A Radanova; M I Eneva; E G Dimitrova; G N Valchev; V T Minchev; M S Taushanova; M V Boneva; T S Karanikolova; R B Gencheva; G A Zhbantov; A I Ivanova; C V Timcheva; B P Pavlov; V G Megdanova; B S Robev; N V Conev
Journal:  Clin Exp Immunol       Date:  2020-08-26       Impact factor: 4.330

3.  Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials.

Authors:  Yoon-Koo Kang; Martin Reck; Paul Nghiem; Yan Feng; Gregory Plautz; Hye Ryun Kim; Taofeek K Owonikoko; Narikazu Boku; Li-Tzong Chen; Ming Lei; Han Chang; Wen Hong Lin; Amit Roy; Akintunde Bello; Jennifer Sheng
Journal:  J Immunother Cancer       Date:  2022-04       Impact factor: 13.751
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.